Literature DB >> 22297028

Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study.

Diana V Do1, Emily W Gower, Sandra D Cassard, David Boyer, Neil M Bressler, Susan B Bressler, Jeffrey S Heier, Joan L Jefferys, Lawrence J Singerman, Sharon D Solomon.   

Abstract

PURPOSE: To determine the sensitivity of time domain optical coherence tomography (OCT) in detecting conversion to neovascular age-related macular degeneration (AMD) in eyes at high risk for choroidal neovascularization (CNV), compared with detection using fluorescein angiography (FA) as the gold standard.
DESIGN: Prospective, multicenter, observational study. PARTICIPANTS: Individuals aged ≥50 years with nonneovascular AMD at high risk of progressing to CNV in the study eye and evidence of neovascular AMD in the fellow eye.
METHODS: At study entry and every 3 months through 2 years, participants underwent best-corrected visual acuity, supervised Amsler grid testing, preferential hyperacuity perimetry (PHP) testing, stereoscopic digital fundus photographs with FA, and OCT imaging. A central Reading Center graded all images. MAIN OUTCOMES MEASURES: The sensitivity of OCT in detecting conversion to neovascular AMD by 2 years, using FA as the reference standard. Secondary outcomes included comparison of sensitivity, specificity, positive predictive value, and negative predictive value of OCT, PHP, and supervised Amsler grid relative to FA for detecting incident CNV.
RESULTS: A total of 98 participants were enrolled; 87 (89%) of these individuals either completed the 24-month visit or exited the study after developing CNV. Fifteen (17%) study eyes had incident CNV confirmed on FA by the Reading Center. The sensitivity of each modality for detecting CNV was: OCT 0.40 (95% confidence interval [CI], 0.16-0.68), supervised Amsler grid 0.42 (95% CI, 0.15-0.72), and PHP 0.50 (95% CI, 0.23-0.77). Treatment for incident CNV was recommended by the study investigator in 13 study eyes. Sensitivity of the testing modalities for detection of CNV in these 13 eyes was 0.69 (95% CI, 0.39-0.91) for OCT, 0.50 (95% CI, 0.19-0.81) for supervised Amsler grid, and 0.70 (95% CI, 0.35-0.93) for PHP. Specificity of the OCT was higher than that of the Amsler grid and PHP.
CONCLUSIONS: Time-domain OCT, supervised Amsler grid, and PHP have low to moderate sensitivity for detection of new-onset CNV compared with FA. Optical coherence tomography has greater specificity than Amsler grid or PHP. Among fellow eyes of individuals with unilateral CNV, FA remains the best method to detect new-onset CNV.
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22297028     DOI: 10.1016/j.ophtha.2011.10.019

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  26 in total

1.  [Fluorescein, indocyanine green and optical coherence tomography angiography in patients with native exudative age-related macular degeneration].

Authors:  L J B Pauleikhoff; K Blobner; K Wehrmann; N Feucht; C P Lohmann; M Maier
Journal:  Ophthalmologe       Date:  2018-07       Impact factor: 1.059

2.  The diagnostic accuracy of spectral-domain optical coherence tomography for neovascular age-related macular degeneration: a comparison with fundus fluorescein angiography.

Authors:  C Wilde; M Patel; A Lakshmanan; R Amankwah; S Dhar-Munshi; W Amoaku
Journal:  Eye (Lond)       Date:  2015-04-24       Impact factor: 3.775

Review 3.  Clinical characteristics and current treatment of age-related macular degeneration.

Authors:  Yoshihiro Yonekawa; Ivana K Kim
Journal:  Cold Spring Harb Perspect Med       Date:  2014-10-03       Impact factor: 6.915

Review 4.  Optical coherence tomography angiography (OCTA) flow speed mapping technology for retinal diseases.

Authors:  Malvika Arya; Ramy Rashad; Osama Sorour; Eric M Moult; James G Fujimoto; Nadia K Waheed
Journal:  Expert Rev Med Devices       Date:  2018-11-22       Impact factor: 3.166

5.  Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration.

Authors:  Yali Jia; Steven T Bailey; David J Wilson; Ou Tan; Michael L Klein; Christina J Flaxel; Benjamin Potsaid; Jonathan J Liu; Chen D Lu; Martin F Kraus; James G Fujimoto; David Huang
Journal:  Ophthalmology       Date:  2014-03-27       Impact factor: 12.079

6.  Safety and efficacy of oral fluorescein angiography in detecting macular edema in comparison with spectral-domain optical coherence tomography.

Authors:  Giulio Barteselli; Jay Chhablani; Su Na Lee; Haiyan Wang; Sharif El Emam; Igor Kozak; Lingyun Cheng; Dirk-Uwe Bartsch; Stanley Azen; William R Freeman
Journal:  Retina       Date:  2013-09       Impact factor: 4.256

7.  Reduced fluorescein angiography and fundus photography use in the management of neovascular macular degeneration and macular edema during the past decade.

Authors:  Eric W Schneider; Prithvi Mruthyunjaya; Nidhi Talwar; Kristen Harris Nwanyanwu; Bin Nan; Joshua D Stein
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-29       Impact factor: 4.799

8.  The use of optical coherence tomography angiography for detecting choroidal neovascularization, compared to standard multimodal imaging.

Authors:  T Soomro; J Talks
Journal:  Eye (Lond)       Date:  2018-03-30       Impact factor: 3.775

9.  Sensitivity and Specificity of OCT Angiography to Detect Choroidal Neovascularization.

Authors:  Ambar Faridi; Yali Jia; Simon S Gao; David Huang; Kavita V Bhavsar; David J Wilson; Andrew Sill; Christina J Flaxel; Thomas S Hwang; Andreas K Lauer; Steven T Bailey
Journal:  Ophthalmol Retina       Date:  2017 Jul-Aug

Review 10.  Aflibercept for neovascular age-related macular degeneration.

Authors:  Salman Sarwar; Elizabeth Clearfield; Mohamed Kamel Soliman; Mohammad Ali Sadiq; Andrew J Baldwin; Mostafa Hanout; Aniruddha Agarwal; Yasir J Sepah; Diana V Do; Quan Dong Nguyen
Journal:  Cochrane Database Syst Rev       Date:  2016-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.